Stifel analyst Annabel Samimy downgraded Supernus Pharmaceuticals (NASDAQ: SUPN) from Buy to Hold with a price target of $23.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE